Dosing and Administration

PRINT THIS PAGE

Administration options

CIMZIA is administered by subcutaneous injection and is supplied in 2 formulations¹:

Lyophilized powder for reconstitution by a healthcare professional
Learn about preparing and administering the lyophilized form of CIMZIA
Prefilled syringe for patient self-injection
Learn about patient self-administration using the CIMZIA prefilled syringe

Depending on patients' needs, CIMZIA can be managed under a pharmacy benefit or a medical benefit. Patients receiving CIMZIA under a pharmacy benefit receive prefilled syringes from their pharmacy. Patients receiving CIMZIA under a medical benefit receive injections administered by a healthcare professional.

Recommended dosing

The recommended dose of CIMZIA for adults with rheumatoid arthritis is 400 mg initially at weeks 2 and 4, followed by 200 mg every 2 weeks.¹ For maintenance dosing, CIMZIA 400 mg every 4 weeks can be considered.¹
Learn more about CIMZIA dosing

Low incidence of injection site reactions and pain, including stinging and burning^2,3

In clinical trials, patients receiving CIMZIA experienced a low incidence of injection site reactions and injection site pain.^2,3

The rate of injection site reactions was 2.3% in RAPID 1 (0 for placebo) and 1.2% in RAPID 2 (0 for placebo)
The rate of injection site pain was 2.0% in RAPID 1 (0 for placebo) and 0 in RAPID 2 (0 for placebo)

Anaphylaxis or serious allergic reactions may occur. Hypersensitivity reactions have been reported rarely following CIMZIA administration.

Prescribing CIMZIA

CIMZIA can be prescribed as monotherapy or in combination with methotrexate or other nonbiological disease-modifying anti-rheumatic drugs (DMARDs). CIMZIA should not be used in combination with biological DMARDs or other anti-TNF therapy due to the increased risk of serious infection.¹

NEXT: Induction and Maintenance Dosing »

Indication
CIMZIA is indicated for the treatment of adults with moderate to severe rheumatoid arthritis (RA).

Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

*The CIMZIA Co-pay Savings Card program is valid for out-of-pocket expenses for CIMZIA for up to 17 uses. The CIMZIA Co-pay Savings Card program is not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

For more information 1-866-4-CIMZIA (1-866-424-6942)

Pain, Fatigue, Disability, and Quality of Life

PEGylated Design

Mechanism of Action